Literature DB >> 6796650

Type A monoamine oxidase catalyzes the intraneuronal deamination of dopamine within nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons in the rat.

K T Demarest, K E Moore.   

Abstract

Clorgyline (0.3-10 mg/kg, i.p.) inhibited type A monamine oxidase (5-hydroxytryptamine as substrate) but not type B monoamine oxidase (phenylethylamine as substrate) in homogenates of rat striatum and olfactory tubercle; deprenyl (0.3-3 mg/kg, i.p.) inhibited type B but not type A monoamine oxidase in these homogenates. The same doses of clorgyline increased concentrations of dopamine in striatum, and dopamine and norepinephrine in the olfactory tubercle, median eminence and posterior pituitary; they also reduced the concentrations of dihydroxyphenylacetic acid and the rate of synthesis of dopamine (DOPA accumulation after a decarboxylase inhibitor) in the same brain regions. On the other hand, the administration of deprenyl at doses that markedly inhibited type B monoamine oxidase did not alter the concentrations of dopamine, norepinephrine and dihydroxyphenylacetic acid or the rate of accumulation of DOPA in these brain regions. In addition, only clorgyline significantly lowered serum concentrations of prolactin. These results that type A monoamine oxidase catalyzes the intraneuronal deamination of dopamine within terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal dopamine neurons.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796650     DOI: 10.1007/BF01249602

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  22 in total

1.  Effects of drugs on regional brain concentrations of dopamine and dihydroxyphenylacetic acid.

Authors:  K Umezu; K E Moore
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

2.  Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity.

Authors:  A S Horn; A C Cuello; R J Miller
Journal:  J Neurochem       Date:  1974-02       Impact factor: 5.372

3.  Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1973-11       Impact factor: 4.030

4.  The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1974-06       Impact factor: 4.030

5.  The organization of tubero-hypophyseal and reticulo-infundibular catecholamine neuron systems in the rat brain.

Authors:  A Björklund; R Y Moore; A Nobin; U Stenevi
Journal:  Brain Res       Date:  1973-03-15       Impact factor: 3.252

6.  Monoamine oxidase in rat arteries: evidence for different forms and selective localization.

Authors:  J F Coquil; C Goridis; G Mack; N H Neff
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

7.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

8.  Noradrenaline metabolizing enzymes in normal and sympathetically denervated vas deferens.

Authors:  B Jarrott; L L Iversen
Journal:  J Neurochem       Date:  1971-01       Impact factor: 5.372

9.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

10.  Accumulation of L-dopa in the median eminence: an index of tuberoinfundibular dopaminergic nerve activity.

Authors:  K T Demarest; K E Moore
Journal:  Endocrinology       Date:  1980-02       Impact factor: 4.736

View more
  6 in total

Review 1.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

2.  Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man.

Authors:  M Strolin Benedetti; A Eschalier; A Lesage; G Dordain; V Rovei; E Zarifian; P Dostert
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Regional differences in the effect of pargyline on dopamine concentrations in the rat hypophysis.

Authors:  M Holzbauer; K Racké; S P Mann; T Cooper; G Cohen; U Krause; D F Sharman
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

4.  Inhibition of rat brain monoamine oxidase type A by 2-aminotetralin and tetrahydroisoquinoline analogues of dopamine.

Authors:  M G Feenstra; T van der Velden; D Dijkstra; O R Hommes; A S Horn
Journal:  Pharm Weekbl Sci       Date:  1983-08-26

5.  The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

Authors:  B Hazelhoff; J B De Vries; D Dijkstra; W de Jong; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

Review 6.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.